Frequency Of Alloantibody In Multiple-Transfused Thalassemia Major Patients And Factors Influencing On Alloimmunization
Alloimmunization in Thalassemia Patient
DOI:
https://doi.org/10.70284/njirm.v7i1.1042Keywords:
Alloantibody, Thalassemia, ImmunogenicityAbstract
Background & Objective: The recommended treatment for beta thalassemia major involves regular blood transfusions, whichstimulate the patient’s immune system and results in the formation of antierytrocyte antibodies usually IgG class. They can result in clinical hemolysis and complication of blood cross matching. The purpose of this study was to determine the frequency of RBC alloantibodies, the type of these antibodies, factors influencing on alloimmunization among multiple- transfused thalassemia major patients. Methodology: ABO blood grouping,Rh (D) typesand Phenotyping done by the electromagnetic technology using Qwalys 3 Diagast. Antibody screening was done by using 3-cell panel followed by11- cell panel of Biorad Corporation. Results: 10 patients developed alloantibodies against RBC Antigen. Among total alloimmunizedpatients, 7.35%were female and 4.27% were male. Majority of alloantibodies were directed against antigen in the Rh and Kell system. i. e. Anti c, Anti E and Anti K. Frequency of Alloantibody positivism is maximum in AB positive patients. From extended Antigen typing of voluntary donors, we can see the frequency of D, C and e Antigens are more than frequency of c, E and K Antigens. Conclusion: Frequency of red cell alloimmunizationwas 5.40% in this study. Alloantibodies found were mainly against Rh blood group systemand Kell system. Red cell alloantibody formation was not influenced by age at first transfusion, number of blood transfusion, splenectomy and leuckodepleted blood transfusion. In our study alloimmunized patients did not revealed any evidence of haemolytic transfusion reaction. The frequency of Antibody positivity depends on immunogenicity of Antigen. Females and group AB patients are showing more frequency of alloimmunization. Routine pretransfusion matching of blood, other than ABO and RhD antigen is not recommended because of low rate of red cell alloimmunization and high cost associated with such testing. [Shah S NJIRM 2016; 7(1):41-46]
References
2. Elghetany M.T, Banki K. Erythrocytic disorders. Henry’s Clinical Diagnosis and Management by Laboratory Methods. 21th ed. Pennsylvania; Elsevier Saunders; 2007. P, 528-9.
3. Ansari S, Moshtaghian PVS Assessment of frequency of alloimmunization and erythrocyte autoimmunization in transfusion dependent thalessemia patients. ActaMedicaIranica. 2008, 46:137-140.
4. Noor Haslina MN, Ariffin N, IlluniHayati I, Roslin H, Red cell immunization in multiply transfused Malay thallasemic patients. Southeast Asian J Trop Med Public Health 5: 1015-1020, 2006.
5. Ameen R, Al-Shemmari S.et al. RBC alloimmunization and autoimmunization among transfusion dependent Arab thalassemia patients. 2003, Transfusion 43: 1604-1610.
6. Kattamis C, Touliatos N, et al, Growth of children with thalessemia : effect of different transfusion regimen. Archives of disease in childhood. 1970, 45: 502-505.
7. Mahboudi F ZS, Merat A, et al. molecular basis of thallassemia mutation in Fars province, Iran, 1996, Med Sci21:104.
8. Salama MA, Sadek NA et.al. Erythrocyte autoantibodies and expression of CD59 on the surface of red blood cells of poly transfused patients with beta thalassemia major. Br J Biomed Sci 2004, 61: 88-92.
9. Singer ST, Wu V, Mignacca R, et. al, Alloimmunization and erythrocyte autoimmunization in transfusion dependent thallessemia patients of predominantly asian descent. Blood,2000, 96:3369-3373.
10. Kruatrachue M, SirisinhaS,et.al. An Association between thalassemia and autoimmune haemolytic anaemia (AIHA). Scand J Haematol. 1980; 25:259-263.
11. Argiolu F, Diana G, et.al. High dose intravenous immunoglobulin in the management of autoimmune hemolyticanemia complicating thalassemia major. ActaHaematol. 1990;83:65-68.
12. Cianciulli P, Sorrentino F, MorinoL,et al. Radiotherapy combined with erythropoietine for the treatment of extramedullaryhematopoiesis in an alloimmunized patient with thalessemiaintermedia. Ann Hematol. 1996; 73:379-381.
13. Gupta R, Singh B, et.al. Red cell Alloimmunization in Routinely Transfused Patients of Beta Thalassemia Major. IJBTI.2010, 1: 1-4.
14. Ness PM, ShireyRS,et.al. The differentiation of delayed hemolytic transfusion reaction :incidence, long term serologic findings, and clinical significance. Transfusion. 1990;34:688-693.
15. Ness PM. To match or not to match: the question for chronically transfused patients with sickle cell anemia . Transfusion 1994; 34:558-561.
16. Fluit CRMG, Kunst VAJM, Drenth-Schonk AM. Incidence of Red Cell Antibodies after multiple blood transfusion. Transfusion. 1990;30:532-535.
17. Sirchia G, Zanella A, Parravivini A, et al. Red Cell Alloantibodies in thalassemia major. Transfusion 25; 110-112, 1985.
18. Tormey CA, Fisk J, Stack G, Red Blood Cell Alloantibody frequency, specificity and properties in a population of male military veterans. Transfusion 48; 2069-2076, 2008.
19. Shamsian BS, Arzanian MT, Shamshiri AR, et al. Frequency of red cell alloimmunization in patient with beta major thalessemia in an Iranian referral Hospital, Iran J Pediater 18; 149-153, 2008.
20. HO HK, Ha SY, et alAlloimmunization in Hong Kong .southern Chinese transfusion dependent thalassemia patients. 2001, Blood 97: 3999-4000.
21. Michail- Merianou V, Pamphill- Panousopoulou L, et.al. Alloimmunization to Red cell antigen in thalassemia: Comparative Study of Usual versus Better-Match transfusion programmes : 1987,Vox sanguinis 52, 95-98.
22. http://www.Diagast.com/page/77/1120/E-M- Technology, opened on 17thDec2015
23. Technical Manual of the American Association of Blood Banks, 1117 North 19th Street,
Suite- 600. Arlington. V.A.-22209. 12th Edition 1996.
24. Weatherall DJ. Disorder of globin synthesis:bthalassemia. Williams hematology. 7thed .
New York :McGraw- Hill; 2006. P.633-57.
25. Borgna-Pignatti C, Galanello R. Thalassemias and related disorders: Quantitative disorders of Hemoglobin synthesis. Wintrob’s Clinical Hematology. 11th ed. Philadelphia : Lippincott Williams and wilkins; 2004. P. 1332-5.
26. M. HadiSadeghian, M Reza Keramati, Alloimmunization among transfusion dependent thalassemia patients; Asian J Transfusion Science – vol 3, Issue 2, July 2009.
27. Bhatti FA, Salamat N, et.al.Red cell immunization in beta thalessemia major. J CollPhysicians Surg Pak 2004; 14: 657-60.
28. Spanos T, Karageorga M, et.al. Red cell Alloantibodies in patients with thalassemia . Vox
Sang 1990; 58 ;50-5.
29. MerilynWiler, The Rh Blood Group System; Modern Blood Banking & Transfusion Practices: 5th Edition ; Denise M. Harmening: Page 142.
30. Regina M. Leger,Loni Calhoun: Other Major Blood Group System ; Modern Blood Banking & Transfusion Practices: 5th Edition. Harmening: Page-176.
31. Frabetti F., Musiani D., et.al. White Cell Apoptosis in packed red cells. Transfusion,1998, 38, 1082-1089.
32. Mincheff, M. Changes in donor leukocytes during blood storage. Implications on post-transfusion Immunomodulation and transfusion associated GVHD. 1998,Vox-Sang, 74 (suppl. 2), 189-200.
33. Ghio M., Contini P., Mazzei C. Soluble HLA class xI, HLA class II, and FAS ligand in blood components: a possible key to explain the immunomodulatory effects of allogenic blood transfusion. 1999,Blood, 93, 1770-1777.
34. Martelli A. M., Tazzare P.L. Nuclear matrix protein is released from apoptotic white cells during cold(1-6 C) storage of concentrated red cell units and might induce antibody response in multiply transfused patients. 2000,Transfusion, 40, 169-177.
35. Pistillo, M.P., Tazzari,P.L. Patients with neoplastic and non neoplastichematological disease acquire CTLA-4 antibodies after blood transfusion. 2001, Transfusion 41, 462-469.
